Liraglutide: A Once-Daily Incretin Mimetic for the Treatment of Type 2 Diabetes Mellitus
The DOI matches its Crossref record; 19 of the 19 references it cites were found in a registry or an index.
Abstract
Objective: To review the pharmacology, pharmacokinetics, efficacy, and safety of liraglutide, a glucagon-like peptide 1 (GLP-1) analog for the treatment of type 2 diabetes mellitus. Data Sources: A MEDLINE search (1966–May 2009) was conducted for English-language articles using the terms glucagon-like peptide 1, incretin mimetic, NN2211, and liraglutide. Abstracts presented at the American Diabetes Association and European Association for the Study of Diabetes annual meetings in 2006, 2007, and 2008 were also searched for relevant data. Study Selection and Data Extraction: Articles pertinent to the pharmacology, pharmacokinetics, efficacy, and safety of liraglutide were reviewed. Data Synthesis: Liraglutide is a GLP-1 analog with pharmacokinetic properties suitable for once-daily administration. Clinical trial data from large, controlled studies demonstrate the effectiveness of liraglutide in terms of hemoglobin A 1c (A1C) reduction, reductions in body weight, and the drug's low risk for hypoglycemic events when used as monotherapy. Data also support benefits of liraglutide therapy on β-cell responsiveness to glucose, with animal and in vitro data indicating potential benefits in β-cell mass and neogenesis with liraglutide treatment. Liraglutide has been studied as monotherapy and in combination with metformin, glimepiride, and rosiglitazone for the treatment of type 2 diabetes. Additionally, comparative data with insulin glargine and exenatide therapy are available from Phase 3 trials providing practitioners valuable clinical data on which to base clinical decision making. Overall, liraglutide is well tolerated with dose-dependent nausea, vomiting, and diarrhea being the most commonly reported adverse events in clinical trials. Conclusions: Once-daily administration may provide a therapeutic advantage for liraglutide over twice-daily exenatide, with similar improvements in A1C and body weight observed when liraglutide was compared with exenatide. The glucose-dependent mechanism of insulin release with GLP-1 agonist therapy holds potential clinical significance in the management of postprandial hyperglycemic excursions, with minimal risk of hypoglycemia.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Nathan, D. M., Buse, J. B., Davidson, M. B., Ferrannini, E., Holman, R. R., Sherwin, R., & Zinman, B. (2009) · Diabetes Care · doi:10.2337/dc08-9025 · Cited by 3,834
Nauck, M. A., Heimesaat, M. M., Orskov, C., Holst, J. J., Ebert, R., & Creutzfeldt, W. (1993) · Journal of Clinical Investigation · doi:10.1172/jci116186 · Cited by 1,651
Glucagon-like peptide 1 promotes satiety and suppresses energy intake in humans.
Flint, A., Raben, A., Astrup, A., & Holst, J. J. (1998) · Journal of Clinical Investigation · doi:10.1172/jci990 · Cited by 1,402
Economic costs of diabetes in the U.S. in 2007
American Diabetes Association (2008) · Diabetes Care · doi:10.2337/dc08-9017 · Cited by 1,323
Reduced incretin effect in Type 2 (non-insulin dependent) diabetes
Nauck, M., Stöckmann, F., Ebert, R., & Creutzfeldt, W. (1986) · Diabetologia · doi:10.1007/bf02427280 · Cited by 1,307
Nauck, M., Frid, A., Hermansen, K., Shah, N. S., Tankova, T., Mitha, I. H., Zdravkovic, M., Düring, M., Matthews, D. R., & for the LEAD-2 Study Group (2009) · Diabetes Care · doi:10.2337/dc08-1355 · Cited by 1,129
Garber, A., Henry, R., Ratner, R., Garcia-Hernandez, P. A., Rodriguez-Pattzi, H., Olvera-Alvarez, I., Hale, P. M., Zdravkovic, M., & Bode, B. (2009) · The Lancet · doi:10.1016/s0140-6736(08)61246-5 · Cited by 1,057
NAUCK, M. A., HOMBERGER, E., SIEGEL, E. G., ALLEN, R. C., EATON, R. P., EBERT, R., & CREUTZFELDT, W. (1986) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem-63-2-492 · Cited by 874
Plasma Insulin Response to Oral and Intravenous Glucose Administration1
ELRICK, H., STIMMLER, L., HLAD, C. J., & ARAI, Y. (1964) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem-24-10-1076 · Cited by 857
The Influence of GLP-1 on Glucose-Stimulated Insulin Secretion
Kjems, L. L., Holst, J. J., Vølund, A., & Madsbad, S. (2003) · Diabetes · doi:10.2337/diabetes.52.2.380 · Cited by 582
Research works printed but not linked: 54
- 10.1210/jc.2002-021545 · DOI · Paper page
- Novo Nordisk. Liraglutide press releases. www.novonordisk.com/science/pipeline/liraglutide-press-releases.asp (accessed 2009 Mar 2).
- 10.2337/diacare.26.10.2929 · DOI · Paper page
- 10.3109/00365529609009147 · DOI · Paper page
- 10.1177/0145721706297451 · DOI
- 10.1152/ajpendo.00099.2005 · DOI
- 10.1210/jc.2003-030738 · DOI · Paper page
- 10.1007/s00125-004-1342-6 · DOI · Paper page
- 10.2337/diabetes.50.3.609 · DOI · Paper page
- 10.1007/s001250050664 · DOI · Paper page
- 10.1210/endo-123-4-2009 · DOI · Paper page
- Willms B, 1996, J Clin Endocrinol Metab, 81, 327
- Nauck MA, 1997, Am J Physiol, 273, E981-8
- 10.2337/diabetes.49.5.741 · DOI · Paper page
- 10.2337/diabetes.48.12.2358 · DOI · Paper page
- 10.1002/dmrr.357 · DOI · Paper page
- 10.1038/nbt1115 · DOI · Paper page
- 10.1517/13543784.15.8.887 · DOI
- 10.2337/diab.44.9.1126 · DOI · Paper page
- 10.1021/jm9909645 · DOI · Paper page
- 10.1517/13543784.16.2.231 · DOI · Paper page
- Knudsen LB, 1999, Diabetologia, 42, A199
- Steensgaard DB, 2008, Diabetes, 57, A164
- Bjornsdottir I, 2008, Diabetologia, 51, S356
- Flint A, 2007, Diabetes, 56, A0545P
- Jacobsen LV, 2007, Diabetes, 56, A0513P
- 10.1177/0091270006288215 · DOI
- 10.5414/CPP46273 · DOI
- 10.1016/j.diabres.2008.03.018 · DOI
- 10.1111/j.1463-1326.2008.00861.x · DOI
- 10.2337/dc06-2593 · DOI · Paper page
- 10.2337/dc07-0310 · DOI
- Vilsboll T, 2006, Diabetes, 55, A2007PO
- 10.1055/s-2006-924230 · DOI · Paper page
- 10.1177/0091270006288215 · DOI
- 10.1111/j.1464-5491.2005.01567.x · DOI
- 10.2337/diacare.27.8.1915 · DOI · Paper page
- 10.2337/diacare.27.6.1335 · DOI · Paper page
- 10.2337/diabetes.52.7.1786 · DOI · Paper page
- 10.1016/S0928-0987(03)00073-3 · DOI
- 10.2337/diabetes.51.2.424 · DOI · Paper page
- Marre M, 2008, Diabetes, 57, A4, 10.2337/db07-1569 · DOI
- Zinman B, 2008, Diabetologia, 51, S359
- Blonde L, Rosenstock J, Sesti G, Liraglutide: superior glycemic control vs exenatide when added to metformin and/or SU in type 2 diabetes. 2008 CDA/CSEM Professional Conference and Annual Meetings, abstract 107. www.diabetes.ca/files/for-professionals/conference-abstract-book.pdf (accessed 2009 Mar 6).
- 10.1038/sj.bjp.0705397 · DOI · Paper page
- 10.1152/ajpendo.00030.2002 · DOI · Paper page
- Hui H, 2006, Diabetes, 55, A1933
- 10.1677/JOE-08-0468 · DOI · Paper page
- 10.1111/j.1464-5491.2008.02484.x · DOI · Paper page
- Nauck MA, 2003, Diabetes, 52, A128
- 10.1517/14740330802432003 · DOI
- Ahmad SR, 2008, N Engl J Med, 358, 1970
- 10.1016/j.clinthera.2006.05.006 · DOI
- 10.1111/j.1464-5491.2005.01567.x · DOI
Cited by
van Can, J., Sloth, B., Jensen, C. B., Flint, A., Blaak, E. E., & Saris, W. H. M. (2014) · International Journal of Obesity · doi:10.1038/ijo.2013.162 · Cited by 537
Anti-inflammatory role of glucagon-like peptide 1 receptor agonists and its clinical implications
Alharbi, S. H. (2024) · Therapeutic Advances in Endocrinology and Metabolism · doi:10.1177/20420188231222367 · Cited by 358
The structure and function of the glucagon‐like peptide‐1 receptor and its ligands
Donnelly, D. (2012) · British Journal of Pharmacology · doi:10.1111/j.1476-5381.2011.01687.x · Cited by 292
Sun, F., Wu, S., Wang, J., Guo, S., Chai, S., Yang, Z., Li, L., Zhang, Y., Ji, L., & Zhan, S. (2015) · Clinical Therapeutics · doi:10.1016/j.clinthera.2014.11.008 · Cited by 232
on behalf of the NN8022-1807 Investigators, Lean, M. E. J., Carraro, R., Finer, N., Hartvig, H., Lindegaard, M. L., Rössner, S., Van Gaal, L., & Astrup, A. (2014) · International Journal of Obesity · doi:10.1038/ijo.2013.149 · Cited by 210
Metadata
- Authors
- Neumiller, J. J., & Campbell, R. K.
- Venue
- Annals of Pharmacotherapy
- Publisher
- SAGE Publications
- Published
- 2009-07-28
- Volume
- 43
- Issue
- 9
- Pages
- 1433-1444
- ISSN
- 0012-6578 (ISSN-L)
- 1060-0280
- 1542-6270
- OpenAlex
- W2111901007
- Cited by
- 63
- References
- 19
- FWCI
- 4.57
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- journals.sagepub.com/page/policies/text-and-data-mining-license (tdm)
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Liraglutide: A Once-Daily Incretin Mimetic for the Treatment of Type 2 Diabetes Mellitus. https://app.cochat.ai/papers/10.1345/aph.1m134
- The paper
- Neumiller, J. J., & Campbell, R. K. (2009). Liraglutide: A Once-Daily Incretin Mimetic for the Treatment of Type 2 Diabetes Mellitus. Annals of Pharmacotherapy. https://doi.org/10.1345/aph.1m134
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.